The host STING pathway at the interface of cancer and immunity
about
Activation of Stimulator of Interferon Genes in Hepatocytes Suppresses the Replication of Hepatitis B Virus.Activation of cGAS-dependent antiviral responses by DNA intercalating agents.Dendritic cells in cancer: the role revisited.Dendritic Cells and Cancer Immunity.Gene-expression profiling to predict responsiveness to immunotherapy.TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.Mechanisms of Resistance to Immune Checkpoint Antibodies.Immune Diseases Associated with TREX1 and STING Dysfunction.Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.The immune contexture in cancer prognosis and treatment.Listening to each other: Infectious disease and cancer immunology.Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists.TRIM29 promotes DNA virus infections by inhibiting innate immune response.ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors.The Next Frontier: Head and Neck Cancer Immunoprevention.Emerging Alphaviruses are Sensitive to Cellular States Induced by a Novel Small Molecule Agonist of the STING Pathway.Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells.Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.Precision Therapy of Head and Neck Squamous Cell Carcinoma.A novel transcript isoform of STING that sequesters cGAMP and dominantly inhibits innate nucleic acid sensing.STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.Immune oncology, immune responsiveness and the theory of everything.Small-Molecule Targets in Tumor ImmunotherapyTrial Watch: Immunostimulation with recombinant cytokines for cancer therapyDNA repair defects and implications for immunotherapyRecent advances in understanding dendritic cell development, classification, and phenotypePerspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transferRoles for the IKK-Related Kinases TBK1 and IKKε in CancerNovel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways
P2860
Q38697029-0BCDCC4C-20E5-4BFE-8394-FE563BAE8300Q38742855-17DA07B1-32C3-46BC-A296-0DCDADBF038BQ38963934-EEABD78B-4AEC-4AE4-A20A-BBA20DA259ECQ38994017-D7D08823-5ED1-41F2-833E-963683E6CCDEQ39005203-194E249D-C248-4989-9D48-01AC0EAE3B6EQ39160959-3F5E16AB-0869-44B6-9CAD-8E237356E48BQ39185608-1C061AB0-B36A-4526-BB33-118F04E0B538Q39285868-926815C1-0933-42EA-AA3F-5A196630E02AQ39389626-5175D317-2337-4186-9D1C-B4C6682B5124Q39456999-0F71F835-F513-4D9C-95FC-6103C88D4A3EQ40103816-05CD3645-CA69-4A5E-A546-A938BC99D249Q40131682-4AD7AAC2-C981-4124-8A6A-57B2B93571D8Q41923395-DDCF1490-8C15-40B0-BAEE-5606C751E883Q42378848-8F0F17CC-D341-4A47-ADDB-EB3816D5C9E8Q42906483-A9388A17-CD75-4A8B-9FB9-3AEFE8E61A4CQ46115310-681DF114-2CD5-417B-BF89-1F5CAD73673FQ47269135-6CB0F63B-5A60-4AF8-AD30-4B98BBC20B56Q47359765-0EA5D655-B40F-4FD3-99D4-E5DB35E82F07Q47843948-AEA94CBB-45A9-483D-802C-82625B5D1746Q47970734-9B78B994-073F-4D2E-BC71-6AC9819582E9Q50026427-BA34CF87-5D29-4E4C-BADB-ECC8719E18A9Q52353493-20E83F3E-2527-4F4D-A730-54BBBEEE434EQ52568331-C068DBF4-00E3-4284-8096-8E254A12E0DAQ52591781-02E9C7F3-73BA-4B4F-B81D-1CF75B3BF009Q52652027-DDD173F3-AE87-43A2-A615-65268239F5CAQ52714689-B5B28D0B-CD68-4BE8-A24A-7ED6CA7339BAQ53047113-A696D60F-3AB0-46EB-9545-3319B0B72907Q55287125-E262DBDF-47F5-49F6-8BED-18B2A30DB424Q55487467-14091147-D61C-4F55-82D0-6493FA770E8EQ56890719-62688CD7-1578-418F-B947-2BE3251D130CQ56892924-B22D68A3-FC29-4386-B84C-E5C2F78711AFQ57057014-45AF4168-8DFA-4877-BBF7-40AA66EFFE13Q57821272-683CA85D-C481-406E-BF56-FBDD48924144Q58699214-FB4F932C-69FA-4B55-AFC3-532E9B0777ABQ58737053-0B03DE7E-6A57-4AAE-A182-7D4451EB9F63Q58804719-49BD69A7-9E34-473C-924A-F5799801C2F5
P2860
The host STING pathway at the interface of cancer and immunity
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The host STING pathway at the interface of cancer and immunity
@en
The host STING pathway at the interface of cancer and immunity.
@nl
type
label
The host STING pathway at the interface of cancer and immunity
@en
The host STING pathway at the interface of cancer and immunity.
@nl
prefLabel
The host STING pathway at the interface of cancer and immunity
@en
The host STING pathway at the interface of cancer and immunity.
@nl
P2093
P2860
P356
P1476
The host STING pathway at the interface of cancer and immunity
@en
P2093
Leticia Corrales
Sarah M McWhirter
Thomas F Gajewski
Thomas W Dubensky
P2860
P304
P356
10.1172/JCI86892
P407
P577
2016-07-01T00:00:00Z